State medical marijuana laws, cannabis use and cannabis use disorder among adults with elevated psychological distress
Copyright © 2020 Elsevier B.V. All rights reserved..
BACKGROUND: Cannabis use and cannabis use disorder are more prevalent in U.S. states with medical marijuana laws (MMLs), as well as among individuals with elevated psychological distress. We investigated whether adults with moderate and serious psychological distress experienced greater levels of cannabis use and/or disorder in states with MMLs compared to states without MMLs.
METHODS: National Survey of Drug Use and Health data (2013-2017) were used to compare past-month cannabis use, daily cannabis use, and cannabis use disorder prevalence among adults with moderate and serious psychological distress in states with versus without MMLs. We executed pooled multivariable logistic regression analyses to test main effects of distress, MMLs and their interaction, after adjustment.
RESULTS: Compared to states without MMLs, states with MMLs had higher adjusted prevalence of past-month use (11.1 % vs. 6.8 %), daily use (4.0 % vs. 2.2 %), and disorder (1.7 % vs. 1.2 %). Adults with moderate and serious psychological distress had greater adjusted odds of any use (AORs of 1.72 and 2.22, respectively) and of disorder (AORs of 2.17 and 2.94, respectively), compared to those with no/mild distress. We did not find evidence of an interaction between MMLs and distress category for any outcome.
CONCLUSIONS: Associations between elevated distress and cannabis use patterns are no greater in states with MML. However, cannabis use is more prevalent in MML states. Thus, higher base rates of cannabis use and disorder among adults with elevated distress are proportionally magnified in these states.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:215 |
|---|---|
| Enthalten in: |
Drug and alcohol dependence - 215(2020) vom: 01. Okt., Seite 108191 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McBain, Ryan K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CUD |
|---|
| Anmerkungen: |
Date Completed 12.03.2021 Date Revised 02.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drugalcdep.2020.108191 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313117845 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313117845 | ||
| 003 | DE-627 | ||
| 005 | 20231225145858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drugalcdep.2020.108191 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313117845 | ||
| 035 | |a (NLM)32736294 | ||
| 035 | |a (PII)S0376-8716(20)30356-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a McBain, Ryan K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a State medical marijuana laws, cannabis use and cannabis use disorder among adults with elevated psychological distress |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2021 | ||
| 500 | |a Date Revised 02.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Cannabis use and cannabis use disorder are more prevalent in U.S. states with medical marijuana laws (MMLs), as well as among individuals with elevated psychological distress. We investigated whether adults with moderate and serious psychological distress experienced greater levels of cannabis use and/or disorder in states with MMLs compared to states without MMLs | ||
| 520 | |a METHODS: National Survey of Drug Use and Health data (2013-2017) were used to compare past-month cannabis use, daily cannabis use, and cannabis use disorder prevalence among adults with moderate and serious psychological distress in states with versus without MMLs. We executed pooled multivariable logistic regression analyses to test main effects of distress, MMLs and their interaction, after adjustment | ||
| 520 | |a RESULTS: Compared to states without MMLs, states with MMLs had higher adjusted prevalence of past-month use (11.1 % vs. 6.8 %), daily use (4.0 % vs. 2.2 %), and disorder (1.7 % vs. 1.2 %). Adults with moderate and serious psychological distress had greater adjusted odds of any use (AORs of 1.72 and 2.22, respectively) and of disorder (AORs of 2.17 and 2.94, respectively), compared to those with no/mild distress. We did not find evidence of an interaction between MMLs and distress category for any outcome | ||
| 520 | |a CONCLUSIONS: Associations between elevated distress and cannabis use patterns are no greater in states with MML. However, cannabis use is more prevalent in MML states. Thus, higher base rates of cannabis use and disorder among adults with elevated distress are proportionally magnified in these states | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a CUD | |
| 650 | 4 | |a Cannabis | |
| 650 | 4 | |a Marijuana legalization laws | |
| 650 | 4 | |a Mental health | |
| 650 | 4 | |a Policy analysis | |
| 650 | 4 | |a Psychological distress | |
| 650 | 7 | |a Hallucinogens |2 NLM | |
| 650 | 7 | |a Medical Marijuana |2 NLM | |
| 700 | 1 | |a Wong, Eunice C |e verfasserin |4 aut | |
| 700 | 1 | |a Breslau, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Shearer, Amy L |e verfasserin |4 aut | |
| 700 | 1 | |a Cefalu, Matthew S |e verfasserin |4 aut | |
| 700 | 1 | |a Roth, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Burnam, M Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Collins, Rebecca L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug and alcohol dependence |d 1980 |g 215(2020) vom: 01. Okt., Seite 108191 |w (DE-627)NLM000147869 |x 1879-0046 |7 nnns |
| 773 | 1 | 8 | |g volume:215 |g year:2020 |g day:01 |g month:10 |g pages:108191 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drugalcdep.2020.108191 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 215 |j 2020 |b 01 |c 10 |h 108191 | ||